Initial clinical outcomes of Forge Medical’s VasoStat haemostasis device were presented at the European Congress of Radiology (ECR) (4–8 March, Vienna, Austria).
Timothy Clark, cofounder and chief executive officer of Forge Medical, said: “Within a cohort of patients with challenging anatomy who underwent a spectrum of dialysis access interventions, the VasoStat device achieved 96% clinical success in producing haemostasis following removal of up to 10 French sheaths, no instances of haematoma or pseudoaneurysm. We are very pleased and encouraged that the unique mechanism of the VasoStat produces a safe and effective means of puncture site haemostasis following interventional procedures.”
